Premium
Advanced ovarian cancer: Primary treatment with surgery, radiotherapy, and chemotherapy
Author(s) -
Griffiths C. Thomas,
Grogan Richard H.,
Hall Thomas C.
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197201)29:1<1::aid-cncr2820290102>3.0.co;2-y
Subject(s) - medicine , radiation therapy , chemotherapy , surgery , ovarian cancer , stage (stratigraphy) , regimen , primary tumor , cancer , metastasis , paleontology , biology
Surgery, radiotherapy, and chemotherapy can each palliate advanced ovarian cancer. A combination of these needs assessment. Sixty patients with pelvic or abdominal dissemination received postoperative irradiation. Fifteen Stage II and 19 Stage III patients having more than half the tumor excised and no palpable disease postoperatively (Group A) had median survival times (MST) of 39 and 26 months. The MST of 26 Stage III patients with palpable masses (Group B) was 9.5 months. Thirteen Group A patients receiving irradiation plus mustard therapy had a MST of 64+ months while 19 Group A patients with irradiation alone had a MST of 26 months. The mean free interval to recurrence was 18.5 months in the former category and 13.5 months in the latter (p = .02). In Group B, similar response rates occurred with irradiation or irradiation plus mustard therapy, but the latter regimen induced more complete responses of greater duration with doubling of the MST. These findings suggest that survival time in advanced ovarian cancer is inversely proportional to the residual tumor volume after primary therapy, and reduction in tumor volume by surgery and irradiation is enhanced by chemotherapy.